Source: International Congress 2017 – GR2 Lung Cancer Grand Round



Rating:

Share or cite this content

Citations should be made in the following way:
Nir Peled (Hod Hasharon, Israel). Eminence or evidence based ? – personalised diagnostic-therapeutic sequences in a molecular altered advanced NSCLC patient. International Congress 2017 – GR2 Lung Cancer Grand Round

Member's Comments

No comment yet.

Related content which might interest you: Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? Source: Eur Respir J 2014; 44: 1011-1022 Year: 2014 Modern staging in lung cancer: from the current multidisciplinary process to novel approaches Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the radiotherapist Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Diagnostic-therapeutic sequences in advanced NSCLC: how to best standardise and personalise your strategies Source: International Congress 2017 – The latest in lung cancer Year: 2017 Is EBUS sampling adequate for molecular testing in patients with advanced NSCLC? Source: Virtual Congress 2020 – Current and contemporary practices in endobronchial ultrasound Year: 2020 Approaches in patients with locally advanced NSCLC: a surgeon's perspective Source: Eur Respir Monogr 2015; 68: 167-177 Year: 2015 What specific issues arise in the management of elderly patients with advanced NSCLC? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 New treatment concepts in stage IV NSCLC: personalized multidisciplinary approaches Source: Virtual Congress 2021 – Hot topics in thoracic oncology Year: 2021 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the thoracic surgeon Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 Early, locally advanced and metastasised NSCLC: core strategies from the perspective of the (pneumo) oncologist Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Approaches in patients with locally advanced NSCLC: a radiation oncologist's perspective Source: Eur Respir Monogr 2015; 68: 178-185 Year: 2015 Integration of molecular testing in the classification of NSCLC: the French experience Source: International Congress 2014 – The more in-depth classification of lung cancer: relevance for patients and science Year: 2014 Molecular biology of advanced NSCLC and survival: seeking the best therapy Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Patient perspectives and experience on the diagnostic pathway of lung cancer – a qualitative study Source: International Congress 2018 – Contemporary respiratory care: symptoms, the role of the nurse and the organisation of care Year: 2018 Multimodal therapeutic approach for locally advanced NSCLC in everyday practice Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Patients referred to a lung cancer clinic – does a clinical assessment at the outset have an impact on the investigations requested? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 The clinical benefit of personalised medicine in lung cancer Source: International Congress 2014 – Understanding the benefit of current personalised medicine platforms Year: 2014 Challenges in molecular testing in lung cancer patients with advanced disease Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016